Billiontoone (BLLN) – Research Analysts’ Recent Ratings Updates

Several analysts have recently updated their ratings and price targets for Billiontoone (NASDAQ: BLLN):

• 5/15/2026 – Billiontoone was upgraded by Weiss Ratings from “sell (d)” to “sell (d+)”.
• 5/13/2026 – Billiontoone had its price target raised by Guggenheim from $100.00 to $120.00. They now have a “buy” rating on the stock.
• 5/7/2026 – Billiontoone had its price target raised by JPMorgan Chase & Co. from $120.00 to $125.00. They now have an “overweight” rating on the stock.
• 5/7/2026 – Billiontoone had its price target lowered by BTIG Research from $140.00 to $130.00. They now have a “buy” rating on the stock.
• 5/1/2026 – Billiontoone had its “sell (d)” rating reaffirmed by Weiss Ratings.
• 3/30/2026 – Billiontoone had its price target lowered by Guggenheim from $120.00 to $100.00. They now have a “buy” rating on the stock.

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.